following an abbreviated submission:
durvalumab (Imfinzi®) is accepted for use within NHSScotland.
Indication under review: in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab offers an additional treatment choice in the therapeutic class of PD-1 / PD-L1 (Programmed cell death protein 1 / death ligand 1) inhibitors.
Another PD-1 / PD-L1 inhibitor was accepted for use under the end of life and orphan process.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice281KB (PDF)
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2734
- Indication:
in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 February 2025